Search Results for:
-
Nations Clash In Cartagena Over Biosafety Food Rules
As BioWorld International went to press Tuesday, it was unclear whether the meeting had reached any conclusion, or had broken up without any agreement but with the delegates deciding to meet laterBioWorld International | Wednesday, March 3, 1999 -
Flamel Blames R&D Costs, Phase III Trials For Net Loss
Results In Line With Expectations Chief Financial Officer Barbara Sherrill told BioWorld International that the annual results were broadly in line with expectations, although the company had hoped that revenues from partners might have been higherBioWorld International | Wednesday, March 3, 1999 -
Cortecs Ending Phase III Trials Early To Gather Data
A spokesman told BioWorld International that the European trial was being stopped not to save costs, but because the clinical objectives will be better served by setting up a U.SBioWorld International | Wednesday, March 3, 1999 -
Biota Flu-Drug Rejection Sends Stock Into Nosedive
Biotas chief financial officer, Richard Wardley, told BioWorld International that Glaxo had already expressed its intention of going straight back to the committee to clear up the reasons for this initial rejectionBioWorld International | Wednesday, March 3, 1999 -
MorphoSys IPO To Value Antibody Firm At US$85M
Although analysts and media were disappointed then, interest in the IPO is unchanged, said Simon Moroney, CEO of MorphoSys. There is a lot of interest, not only among private or institutional investors, he told BioWorld International. We are the first biotech company making losses to enter the new marketBioWorld International | Wednesday, March 3, 1999 -
Narcolepsy Research Locates Potential Gene-Marker Cause
Ian Craig, head of molecular genetics at the Social Genetic and Developmental Psychiatry Research Centre at the Institute of Psychiatry in London, told BioWorld International: This is a step forward, a clue to open up further studiesBioWorld International | Wednesday, March 3, 1999 -
D-Pharm Named Top Startup Company In Israeli Healthcare
We're very proud of our recent growth and evolution from a lab-scale incubator to a biopharmaceutical company and are grateful for the honor bestowed on us by our colleagues," Kozak told BioWorld InternationalBioWorld International | Wednesday, March 3, 1999 -
Cobra Therapeutics Plans Financing For Cancer Drug
CEO David Bloxham told BioWorld International the company has "sufficient funds to last until the second half of 2000, based on current programsBioWorld International | Wednesday, February 24, 1999 -
Biovector's IPO Called Off After Lead Banker Pulls Out
Chairman Emile Loria told BioWorld International the lead banker, Paribas, pulled the plug on the operation because of concern about the "after-market" for Biovector's shares, at a time when the Nouveau Marchi is suffering from low liquidityBioWorld International | Wednesday, February 24, 1999 -
Findings On Low-Oxygen Cell Survival Could Mean Improved Heart Treatments
John Martin, professor of cardiovascular medicine at UCL and chief scientific officer of Eurogene, told BioWorld International: "Given the results we already have, we are optimistic that the company should be able to make available treatments that will be beneficial in a variety of disorders that are presently without adequate treatmentBioWorld International | Wednesday, February 24, 1999 -
NeuroSearch Plans Phase II Trials Of Depression Drug
President and CEO Jorgen Buus Larsen told BioWorld International that the efficacy trial of 150 patients at 10 centers will be completed in the third quarter of 1999BioWorld International | Wednesday, February 24, 1999 -
NicOx IPO Seeking $80M For Nitric-Oxide Treatments
You need a multi-mediated, multi-targeted approach to inflammation and pain," Garufi told BioWorld International, and NicOx claims that its NO-NSAID, HCT 1026, provides just thatBioWorld International | Wednesday, February 24, 1999 -
Genset Reports Highest Quarterly Loss Of Year
Profitability By Year's End Not A Target Chief financial officer Deborah Smeltzer told BioWorld International the company is no longer aiming to move into profit by the end of this year, as it had been planningBioWorld International | Wednesday, February 17, 1999 -
Genetically Modified Milk Could Be Next On Shelves
Jost told BioWorld International: "We thought this was a very important nutritional problemBioWorld International | Wednesday, February 17, 1999 -
British Biotech's Marimastat Fails In Pivotal Cancer Study
Elliot Goldstein, CEO of British Biotech, told BioWorld International the study is one of nine under way, "and pancreatic cancer is the hardest to treatBioWorld International | Wednesday, February 17, 1999 -
PowderJect, Ares-Serono Enter $100M Deal For Dry Vaccines
PowderJect's chairman and CEO, Paul Drayson, told BioWorld International the deal will push PowderJect's market capitalization through the US$1 billion barrierBioWorld International | Wednesday, February 17, 1999 -
University Must Pay Fine For Violating GMO Rules
A spokeswoman for the university told BioWorld InternationalBioWorld International | Wednesday, February 10, 1999 -
RiboTargets Wins Grant To Develop Antibiotics
Simon Sturge, CEO of RiboTargets, told BioWorld International the grant "will help us sustain a portfolio of three programsBioWorld International | Wednesday, February 10, 1999 -
Anti-GMO Group, Pollster Differ Over Survey Results
I don't agree with that," Roger Jupp, managing director of Dublin-based Lansdowne, told BioWorld InternationalBioWorld International | Wednesday, February 10, 1999 -
ExonHit, Sosei Sign Deal For Genomics Products
The company's chairman and CEO, Bruno Tocqui, told BioWorld International that ExonHit's customers, in Asia and elsewhere, will have the choice of a product or a serviceBioWorld International | Wednesday, February 10, 1999
Category
Current Filters
- xBioWorld International
Related Keywords
Categories
- x BioWorld International (5382)
- x BioWorld Insight (589)
- x BioWorld Today (330)
- x Bio Perspectives (191)
- x State of the Industry Report (47)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.